<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>CrashDash ‚Ä¢ FAB.L APEX Profile</title>
    <style>
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body { 
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            padding: 20px;
            color: #333;
        }
        .container { max-width: 1200px; margin: 0 auto; }
        
        .header-card {
            background: white;
            border-radius: 16px;
            padding: 30px;
            margin-bottom: 20px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }
        .ticker-badge {
            display: inline-block;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 8px 16px;
            border-radius: 20px;
            font-weight: bold;
            font-size: 18px;
            margin-bottom: 10px;
        }
        .company-name { font-size: 32px; font-weight: 700; margin-bottom: 8px; }
        .company-meta {
            display: flex;
            gap: 20px;
            margin-top: 15px;
            flex-wrap: wrap;
        }
        .meta-item {
            display: flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: #f7fafc;
            border-radius: 8px;
            font-size: 14px;
        }
        .meta-icon { font-size: 18px; }
        
        .score-hero {
            background: linear-gradient(135deg, #f093fb 0%, #f5576c 100%);
            color: white;
            border-radius: 16px;
            padding: 40px;
            margin-bottom: 20px;
            text-align: center;
            box-shadow: 0 10px 40px rgba(0,0,0,0.15);
        }
        .action-display {
            margin-bottom: 20px;
        }
        .scores-row {
            display: flex;
            justify-content: center;
            gap: 40px;
            margin: 30px 0;
        }
        .score-circle {
            width: 140px;
            height: 140px;
            border-radius: 50%;
            background: white;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: center;
            box-shadow: 0 4px 15px rgba(0,0,0,0.1);
        }
        .score-number {
            font-size: 48px;
            font-weight: 800;
            line-height: 1;
        }
        .score-label { font-size: 12px; color: #666; margin-top: 5px; }
        .timing-badge-large {
            display: inline-block;
            padding: 15px 40px;
            border-radius: 30px;
            font-weight: 700;
            font-size: 24px;
            background: rgba(255,255,255,0.2);
            backdrop-filter: blur(10px);
            color: white;
            margin: 20px 0;
        }
        .thesis-line {
            font-size: 18px;
            font-weight: 600;
            color: white;
            background: rgba(255,255,255,0.15);
            backdrop-filter: blur(10px);
            padding: 20px;
            border-radius: 12px;
            margin-top: 20px;
        }
        
        .factors-list {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 15px;
            margin-top: 20px;
        }
        .factor-item {
            background: white;
            padding: 15px;
            border-radius: 12px;
            display: flex;
            align-items: center;
            gap: 10px;
            font-size: 14px;
        }
        .factor-icon { font-size: 20px; }
        
        .cards-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 20px;
            margin-bottom: 20px;
        }
        .card {
            background: white;
            border-radius: 16px;
            padding: 25px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
        }
        .card-title {
            font-size: 18px;
            font-weight: 600;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
            gap: 10px;
        }
        .card-icon { font-size: 24px; }
        
        .stat-row {
            display: flex;
            justify-content: space-between;
            padding: 12px 0;
            border-bottom: 1px solid #f0f0f0;
        }
        .stat-row:last-child { border-bottom: none; }
        .stat-label { color: #666; font-size: 14px; }
        .stat-value { font-weight: 600; font-size: 16px; }
        
        .rally-badge {
            display: inline-block;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
            text-transform: uppercase;
        }
        
        .risk-indicator {
            display: flex;
            align-items: center;
            gap: 15px;
            padding: 15px;
            border-radius: 12px;
            margin-bottom: 10px;
        }
        .risk-high { background: #fee2e2; }
        .risk-icon { font-size: 24px; }
        
        .reason-item {
            padding: 15px;
            background: #f9fafb;
            border-radius: 8px;
            margin-bottom: 12px;
        }
        
        .tag {
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
        }
        
        .footer {
            background: white;
            border-radius: 16px;
            padding: 20px;
            text-align: center;
            color: #666;
            font-size: 13px;
            box-shadow: 0 4px 20px rgba(0,0,0,0.08);
            margin-top: 20px;
        }
        
        .alert-box {
            background: #fef3c7;
            border-left: 4px solid #f59e0b;
            padding: 15px;
            border-radius: 8px;
            margin: 15px 0;
        }
    </style>
</head>
<body>
    <div class="container">
        
        <!-- Header Card -->
        <div class="header-card">
            <div class="ticker-badge">FAB.L</div>
            <div class="company-name">Fusion Antibodies plc</div>
            <div class="company-meta">
                <div class="meta-item">
                    <span class="meta-icon">‚ñ†</span>
                    <span><strong>Sector:</strong> Healthcare</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">¬£</span>
                    <span><strong>Market Cap:</strong> ¬£19,378,391</span>
                </div>
                <div class="meta-item">
                    <span class="meta-icon">‚ó∑</span>
                    <span><strong>Days Active:</strong> 651 days</span>
                </div>
            </div>
        </div>

        <!-- Action & Score Hero Section -->
        <div class="score-hero">
            <div class="action-display">
                <span style="font-size: 32px; font-weight: 800; color: white;">‚óâ WATCH</span>
            </div>
            
            <div class="scores-row">
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">49</div>
                    <div class="score-label">APEX SCORE</div>
                </div>
                <div class="score-circle">
                    <div class="score-number" style="color: #ef4444;">40</div>
                    <div class="score-label">CONFIDENCE</div>
                </div>
            </div>
            
            <div class="timing-badge-large">
                Timing: <span class="rally-badge" style="background: #fef3c7; color: #92400e;">EARLY BUILD</span>
            </div>
            
            <div class="thesis-line">
                WATCH - EARLY_BUILD timing with 49/100 opportunity score
            </div>
        </div>

        <!-- ==================== CRASHDASH INTELLIGENCE - PANIC HUNTER VIEW ==================== -->
        
        <div class="card" style="background: linear-gradient(135deg, #fef3c7 0%, #fde68a 100%); border: 2px solid #f59e0b;">
            <div class="card-title" style="color: #0f172a;">
                <span class="card-icon">üß¨</span>
                CrashDash Intelligence ‚Ä¢ Biotech & Pharma
            </div>
            
            <!-- Fear Meter -->
            <div style="background: white; padding: 24px; border-radius: 14px; margin-bottom: 20px; text-align: center;">
                <div style="font-size: 16px; font-weight: 700; color: #1e293b; margin-bottom: 16px;">üî• PANIC METER</div>
                <div style="display: flex; justify-content: center; align-items: center; gap: 20px; margin-bottom: 16px;">
                    <div style="width: 160px; height: 160px; border-radius: 50%; background: conic-gradient(#f59e0b 255.95999999999998deg, #e5e7eb 255.95999999999998deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                        <div style="width: 130px; height: 130px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                            <div style="font-size: 48px; font-weight: 800; color: #f59e0b;">71</div>
                            <div style="font-size: 12px; color: #64748b; font-weight: 600;">PANIC SCORE</div>
                        </div>
                    </div>
                    <div style="text-align: left; max-width: 400px;">
                        <div style="font-size: 18px; font-weight: 700; color: #f59e0b; margin-bottom: 12px;">HIGH PANIC</div>
                        <div style="font-size: 14px; color: #475569; line-height: 1.6; margin-bottom: 12px;">üü† Fear dominant - watch for reversal signs</div>
                        <div style="font-size: 13px; color: #64748b;">
                            <div>üíî Price: 39/40</div>
                            <div>üìâ Volume: 6/20</div>
                            <div>üîá Social: 6/20</div>
                            <div>üì∞ News: 20/20</div>
                        </div>
                    </div>
                </div>
                
                <!-- CrashHunter Signals -->
                <div style="margin-top: 20px;">
                    <span style="display: inline-block; background: #f59e0b; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">üü† Fear 71/100</span><span style="display: inline-block; background: #10b981; color: white; padding: 6px 14px; border-radius: 20px; font-size: 13px; font-weight: 700; margin: 4px;">üìä Building</span>
                </div>
                
                <!-- Opportunity Flag -->
                <div style="margin-top: 20px; padding: 16px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 10px; color: white; font-weight: 700; font-size: 16px;">üéØ ‚ö†Ô∏è HIGH PANIC + Early timing = Potential accumulation phase</div>
            </div>
            
            <!-- Contrarian Compression Energy Panel -->
            
            <!-- Contrarian Compression Energy Panel -->
            <div style="background: linear-gradient(135deg, #d1fae5 0%, #a7f3d0 100%); padding: 24px; border-radius: 14px; margin-bottom: 20px; border: 3px solid #10b981;">
                <div style="display: flex; align-items: center; gap: 12px; margin-bottom: 20px;">
                    <span style="font-size: 32px;">‚ö°</span>
                    <div style="flex: 1;">
                        <div style="font-size: 20px; font-weight: 800; color: #0f172a; margin-bottom: 4px;">
                            CONTRARIAN COMPRESSION SCORE
                        </div>
                        <div style="font-size: 13px; color: #475569; font-weight: 600;">
                            Signal Congestion Framework ‚Ä¢ Compression = Explosive Potential
                        </div>
                    </div>
                </div>
                
                <!-- Main Score Display -->
                <div style="background: white; padding: 24px; border-radius: 12px; margin-bottom: 20px; text-align: center;">
                    <div style="display: flex; justify-content: center; align-items: center; gap: 30px;">
                        <!-- Circular gauge -->
                        <div style="width: 140px; height: 140px; border-radius: 50%; background: conic-gradient(#10b981 122.4deg, #e5e7eb 122.4deg); display: flex; align-items: center; justify-content: center; box-shadow: 0 4px 20px rgba(0,0,0,0.15);">
                            <div style="width: 110px; height: 110px; border-radius: 50%; background: white; display: flex; flex-direction: column; align-items: center; justify-content: center;">
                                <div style="font-size: 42px; font-weight: 800; color: #10b981;">34</div>
                                <div style="font-size: 11px; color: #64748b; font-weight: 600;">/ 100</div>
                            </div>
                        </div>
                        
                        <!-- Key metrics -->
                        <div style="text-align: left;">
                            <div style="font-size: 16px; font-weight: 700; color: #10b981; margin-bottom: 12px;">üü¢ MILD COMPRESSION (Top 50% - WATCHLIST)</div>
                            <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                                <div><strong>0.4</strong> signals/week</div>
                                <div><strong>3</strong> RSI &lt; 20 events</div>
                                <div><strong>1</strong> escalations detected</div>
                                <div style="color: #10b981; font-weight: 700; margin-top: 6px;">
                                    üíé Historical pop: <strong>+502%</strong>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                
                <!-- Component Breakdown -->
                <div style="background: white; padding: 20px; border-radius: 12px; margin-bottom: 20px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 15px;">
                        üìä 5-COMPONENT BREAKDOWN
                    </div>
                    
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">compression</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">14/40</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 35.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">0.4 signals/week | 3 RSI<20 | 1 escalations | üéØ MILD COMPRESSION</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">intensification</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">5/20</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 25.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;"></div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">volume death</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">Normal volume</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">pop potential</div>
                        <div style="font-weight: 800; font-size: 15px; color: #ef4444;">15/15</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #ef4444; height: 100%; width: 100.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">BIG POPPER - Historical 5x+ (502%)</div>
                </div>
                
                <div style="margin-bottom: 16px;">
                    <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 6px;">
                        <div style="font-weight: 700; font-size: 13px; color: #1e293b; text-transform: uppercase;">accumulation</div>
                        <div style="font-weight: 800; font-size: 15px; color: #10b981;">0/10</div>
                    </div>
                    <div style="background: #e5e7eb; height: 8px; border-radius: 10px; overflow: hidden; margin-bottom: 6px;">
                        <div style="background: #10b981; height: 100%; width: 0.0%; transition: width 0.3s;"></div>
                    </div>
                    <div style="font-size: 12px; color: #64748b; line-height: 1.4;">No accumulation detected</div>
                </div>
                
                </div>
                
                <!-- Contrarian Philosophy -->
                <div style="background: rgba(255,255,255,0.7); padding: 16px; border-radius: 10px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #0f172a; margin-bottom: 8px; font-size: 14px;">
                        üéØ CONTRARIAN WISDOM
                    </div>
                    <div style="font-size: 13px; color: #334155; line-height: 1.6;">
                        <strong>Signal congestion = Compression energy = Explosive potential.</strong><br>
                        When multiple crash signals cluster together with extreme RSI and proven rally history, 
                        it creates a compressed spring effect. More panic = More opportunity for contrarians.
                        <div style="margin-top: 8px; padding: 10px; background: rgba(239,68,68,0.1); border-radius: 6px; font-size: 12px;">
                            <strong style="color: #10b981;">Theory:</strong> High compression scores (60+) historically precede 
                            explosive 10-20x moves when catalysts arrive. This is the foundation of crash hunting.
                        </div>
                    </div>
                </div>
            </div>
            
            
            <!-- Fear vs Facts Contrarian View -->
            <div style="display: grid; grid-template-columns: 1fr 1fr; gap: 15px; margin-bottom: 20px;">
                <div style="background: #fee2e2; padding: 18px; border-radius: 12px; border-left: 4px solid #ef4444;">
                    <div style="font-weight: 700; color: #991b1b; margin-bottom: 12px; font-size: 15px;">üò± FEAR (What Panic Shows)</div>
                    <div style="color: #7f1d1d;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üíî Price destruction: 39/40 points</div><div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üì∞ Negative news: 20/20 points</div>
                    </div>
                </div>
                <div style="background: #dcfce7; padding: 18px; border-radius: 12px; border-left: 4px solid #10b981;">
                    <div style="font-weight: 700; color: #065f46; margin-bottom: 12px; font-size: 15px;">üìä FACTS (What Data Shows)</div>
                    <div style="color: #064e3b;">
                        <div style="padding: 8px 0; font-size: 14px; line-height: 1.5;">‚Ä¢ üìà Historical upside: 488% proven capacity</div>
                    </div>
                </div>
            </div>
            
            <!-- Contrarian Verdict -->
            <div style="background: white; padding: 18px; border-radius: 12px; margin-bottom: 20px; border-left: 4px solid #6366f1;">
                <div style="font-weight: 700; color: #4338ca; margin-bottom: 10px; font-size: 15px;">‚öñÔ∏è Contrarian Verdict</div>
                <div style="font-size: 15px; color: #1e293b; line-height: 1.6; font-weight: 600;">
                    üéØ CONTRARIAN OPPORTUNITY - Fear dominates but facts support recovery potential
                </div>
            </div>
            
            <!-- Industry Crash Patterns -->
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 15px; margin-bottom: 20px;">
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">‚ö†Ô∏è Crash Patterns (Biotech & Pharma)</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Clinical trial failures (Phase 1/2/3)</div><div>‚Ä¢ FDA/EMA rejection or delay</div><div>‚Ä¢ Safety concerns or adverse events</div>
                    </div>
                    <div style="margin-top: 12px; padding: 10px; background: #fef3c7; border-radius: 8px; font-size: 12px; color: #92400e; font-weight: 600;">üö® Active: Patent expiry or IP challenges</div>
                </div>
                <div style="background: white; padding: 18px; border-radius: 12px;">
                    <div style="font-weight: 700; color: #1e293b; margin-bottom: 12px; font-size: 15px;">üöÄ Recovery Paths</div>
                    <div style="font-size: 13px; color: #475569; line-height: 1.8;">
                        <div>‚Ä¢ Positive trial data (efficacy endpoints met)</div><div>‚Ä¢ Regulatory approvals (FDA/EMA)</div><div>‚Ä¢ Partnership deals (big pharma licensing)</div>
                    </div>
                </div>
            </div>
            
            <!-- Catalyst Pipeline -->
            <div style="background: rgba(255,255,255,0.5); padding: 18px; border-radius: 12px; margin-bottom: 20px;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 14px; font-size: 15px;">üìÖ Catalyst Pipeline</div>
                
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Holding(s) in Company</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Holding(s) in Company</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Total Voting Rights</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Issue of Director Shares</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            <div style="padding: 12px; background: white; border-radius: 8px; margin-bottom: 8px; border-left: 4px solid #10b981;">
                <div style="display: flex; justify-content: between; align-items: center; gap: 10px;">
                    <span style="font-size: 18px;">üì¢</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 600; font-size: 14px; color: #1e293b; margin-bottom: 4px;">Placing and Subscription to raise approx ¬£1.4m</div>
                        <div style="font-size: 12px; color: #64748b;">Unknown</div>
                    </div>
                </div>
            </div>
            
            </div>
            
            <!-- CrashDash Decision Matrix -->
            <div style="background: white; padding: 20px; border-radius: 12px; border: 3px solid #f59e0b;">
                <div style="font-weight: 700; color: #1e293b; margin-bottom: 16px; font-size: 16px; text-align: center;">
                    üéØ CRASHDASH DECISION: <span style="color: #f59e0b; font-size: 20px;">WATCH</span>
                </div>
                <div style="font-size: 15px; color: #475569; text-align: center; margin-bottom: 20px; font-weight: 600;">
                    ‚è≥ Monitor for timing regime change or panic escalation
                </div>
                <div style="background: #f8fafc; padding: 16px; border-radius: 10px;">
                    <div style="font-weight: 700; color: #64748b; margin-bottom: 12px; font-size: 13px;">CHECKLIST (4/5 pass)</div>
                    
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üî¥</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Panic Score</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">71/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚úÖ</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Timing Regime</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">EARLY_BUILD</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">‚ö†Ô∏è</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">APEX Quality</div>
                    <div style="font-size: 13px; color: #ef4444; font-weight: 600;">49/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üéØ</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Data Confidence</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">40/100</div>
                </div>
            </div>
            
            <div style="display: flex; align-items: center; gap: 12px; padding: 10px; background: white; border-radius: 8px; margin-bottom: 8px;">
                <span style="font-size: 24px;">üß¨</span>
                <div style="flex: 1;">
                    <div style="font-weight: 600; font-size: 14px; color: #1e293b;">Industry Pattern</div>
                    <div style="font-size: 13px; color: #10b981; font-weight: 600;">1 active</div>
                </div>
            </div>
            
                </div>
            </div>
        </div>
        

        <!-- ==================== AI TRADER INTELLIGENCE (TOP) - TRADER BRIEF V2 ==================== -->
        

        <!-- Decision Summary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óÜ</span>
                Why This Matters
            </div>
            <div class="stat-row"><span>‚Ä¢ APEX 49/100 indicates moderate opportunity quality</span></div><div class="stat-row"><span>‚Ä¢ Timing regime: EARLY_BUILD</span></div><div class="stat-row"><span>‚Ä¢ Historical profile: 2 rallies, 488% best run</span></div>
            
            <div class="alert-box" style="margin-top: 20px;">
                <strong>‚ñ≥ Main Risk:</strong> Confidence 40/100 - full data loaded
            </div>
            
            <div style="margin-top: 20px;">
                <strong>‚óâ Watch Next:</strong>
                <div style="padding: 8px 0;">‚Ä¢ RNS catalysts (funding/operational updates)</div><div style="padding: 8px 0;">‚Ä¢ Volume expansion confirmation</div><div style="padding: 8px 0;">‚Ä¢ Timing regime change signals</div>
            </div>
        </div>

        <!-- ==================== TECHNICAL DETAILS (COLLAPSIBLE) ==================== -->
        
        <div class="card">
          <details style="cursor:pointer;">
            <summary style="font-weight:800; font-size:16px; list-style:none; padding: 10px; background: #f9fafb; border-radius: 8px;">
              üîß Technical Analysis & Scoring Details
            </summary>
            <div style="margin-top:14px;">
              
            <!-- Scoring Breakdown -->
            <div class="card-title" style="margin-top: 20px;">
                <span class="card-icon">‚ñ£</span>
                APEX Score Breakdown
            </div>
            <div class="factors-list">
                <div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Moderate Technical Setup</strong><br><small>Chart quality: 8/20 ‚Ä¢ Score: 10/25 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Massive recovery potential</strong><br><small>Down 92.7% from peak ‚Ä¢ Score: 19/20 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Normal volume</strong><br><small>1.4x average ‚Ä¢ Score: 3/10 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Limited history</strong><br><small>2 previous rallies ‚Ä¢ Score: 5/15 points</small></span></div>
<div class="factor-item"><span class="factor-icon">‚óÜ</span><span><strong>Major upside</strong><br><small>Historical best: +488% ‚Ä¢ Score: 12/20 points</small></span></div>

            </div>
            
            <div style="margin-top: 40px;"></div>
            
            <!-- Exhaustion Metrics -->
            <div class="card-title">
                <span class="card-icon">üìà</span>
                Rally Cycle Position
            </div>
            <div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(150px, 1fr)); gap: 15px; margin: 20px 0;">
                <div style="padding: 15px; background: linear-gradient(135deg, #10b981 0%, #059669 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Current Position</div>
                    <div style="font-size: 32px; font-weight: 800;">309%</div>
                    <div style="font-size: 11px; opacity: 0.8;">from entry</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #3b82f6 0%, #1d4ed8 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Typical Rally</div>
                    <div style="font-size: 32px; font-weight: 800;">488%</div>
                    <div style="font-size: 11px; opacity: 0.8;">historical avg</div>
                </div>
                <div style="padding: 15px; background: linear-gradient(135deg, #f59e0b 0%, #d97706 100%); border-radius: 8px; text-align: center; color: white;">
                    <div style="font-size: 12px; opacity: 0.9; margin-bottom: 5px;">Exhaustion Level</div>
                    <div style="font-size: 32px; font-weight: 800;">0.6x</div>
                    <div style="font-size: 11px; opacity: 0.8;">vs average</div>
                </div>
            </div>
        
            </div>
          </details>
        </div>
        

        <!-- Reasons Buy/Sell -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #10b981;">‚ñ≤</span>
                    Reasons to Buy
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Early stage positioning offers best R:R if catalysts appear</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">timing=EARLY BUILD ‚Ä¢ current return=309.2%</div>
            </div>
            
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Proven winner - previously hit lock-in target</span>
                    <span class="tag" style="background: #f59e0b; color: white;">‚ö° Medium Strength</span>
                </div>
                <div style="font-size: 12px; color: #666;">profit target reached: True</div>
            </div>
            
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon" style="color: #ef4444;">‚ñº</span>
                    Reasons to Sell / Avoid
                </div>
                
            <div class="reason-item">
                <div style="display: flex; justify-content: space-between; align-items: center; margin-bottom: 8px;">
                    <span style="font-weight: 600;">Stale signal - not for active trading</span>
                    <span class="tag" style="background: #ef4444; color: white;">üö® High Risk</span>
                </div>
                <div style="font-size: 12px; color: #666;">historical ‚Ä¢ signal date=2024-05-01</div>
            </div>
            
            </div>
        </div>

        <!-- Trade Plans -->
        <div class="cards-grid">
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üìä</span>
                    Short-Term Trader Playbook
                </div>
                <div style="background: linear-gradient(135deg, #f093fb 0%, #f5576c 20%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px;">
                    <div style="font-size: 18px; font-weight: 600; margin-bottom: 5px;">Watch / Starter</div>
                    <div style="font-size: 14px; opacity: 0.9;">Wait for base + catalyst confirmation; starter position only</div>
                </div>
                <div style="padding: 12px; background: #f9fafb; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Position Size</div>
                    <div style="font-weight: 600;">0-1% until CONFIRMED</div>
                </div>
                <div style="padding: 12px; background: #fef2f2; border-radius: 6px; margin-bottom: 10px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Risk Management</div>
                    <div style="font-weight: 600; color: #dc2626;">Invalidation = breaks recent lows / dilution / suspension</div>
                </div>
                <div style="padding: 12px; background: #f0fdf4; border-radius: 6px;">
                    <div style="font-size: 12px; color: #666; margin-bottom: 3px;">Exit Strategy</div>
                    <div style="font-weight: 600; color: #059669;">Scale out 25% at +15%, 25% at +50%, runner above</div>
                </div>
            </div>
            
            <div class="card">
                <div class="card-title">
                    <span class="card-icon">üíº</span>
                    Long-Term Investor Playbook
                </div>
                <div style="background: linear-gradient(135deg, #667eea 0%, #764ba2 100%); color: white; padding: 15px; border-radius: 8px; margin-bottom: 15px; text-align: center;">
                    <div style="font-size: 32px; margin-bottom: 5px;">‚úó</div>
                    <div style="font-size: 18px; font-weight: 600;">Not Recommended for Investors</div>
                </div>
                <div style="padding: 15px; background: #f9fafb; border-radius: 8px; font-size: 14px; line-height: 1.6;">
                    <strong style="color: #667eea;">üìã Investment Thesis:</strong><br>
                    Unlock after AI triangulation + CONFIRMED timing<br><br>
                    <strong style="color: #667eea;">‚è≥ Time Horizon:</strong><br>
                    N/A<br><br>
                    <strong style="color: #ef4444;">üõ°Ô∏è Exit Rule:</strong><br>
                    N/A
                </div>
            </div>
        </div>

        <!-- Commentary -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚óê</span>
                Executive Commentary
            </div>
            <div style="line-height: 1.6; margin-bottom: 20px;">
                This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 49/100 APEX score. Historical data shows 2 rallies averaging 488% upside. Current position: +309.2%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #10b981;">‚ñ≤ Bull Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Early regime often offers best risk/reward</div>
            </div>
            
            <div style="margin-top: 20px;">
                <strong style="color: #ef4444;">‚ñº Bear Case:</strong>
                <div style="padding: 8px 0;">‚Ä¢ Monitor for breakdown signals</div>
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #f0f9ff; border-radius: 8px;">
                <strong>‚ó∑ Timing Translation:</strong><br>
                Early accumulation phase. Watch for confirmation before committing size.
            </div>
            
            <div style="margin-top: 20px; padding: 15px; background: #fef3c7; border-radius: 8px;">
                <strong>‚óé Confidence Explained:</strong><br>
                Confidence 40/100 reflects full data quality with triangulation loaded.
            </div>
        </div>

        <!-- Data Quality Warning -->
        <div class="card">
            <div class="card-title">
                <span class="card-icon">‚ñ≥</span>
                Data Quality Notice
            </div>
            <div class="alert-box">
                <strong>Analysis Mode:</strong> HISTORICAL_ONLY<br>
                <strong>Impact:</strong> HIGH
            </div>
            <div class="risk-indicator risk-high"><span class="risk-icon">‚ñ≥</span><div><div style="font-weight: 600;">AI insights from Groq LLM</div></div></div>

            <div style="margin-top: 15px; font-size: 13px; color: #666;">
                Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk.
            </div>
        </div>

        <!-- ==================== TOP 5 RECENT RNS NEWS ==================== -->
        
        <div class="card" style="border-top: 3px solid #3b82f6;">
            <div class="card-title" style="margin-bottom: 20px;">
                <span class="card-icon">üì∞</span>
                Top 5 Recent RNS Announcements
            </div>
            
            <!-- Bloomberg-style Disclaimer Box -->
            <div style="
                margin-bottom: 20px;
                padding: 16px 18px;
                background: linear-gradient(135deg, rgba(59, 130, 246, 0.05) 0%, rgba(59, 130, 246, 0.02) 100%);
                border: 1px solid rgba(59, 130, 246, 0.2);
                border-left: 3px solid #3b82f6;
                border-radius: 8px;
                font-family: 'Courier New', monospace;
                box-shadow: 0 2px 4px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: flex-start; gap: 12px;">
                    <span style="font-size: 18px; margin-top: 2px; flex-shrink: 0;">üéØ</span>
                    <div style="flex: 1;">
                        <div style="font-size: 12px; font-weight: 700; color: #1e40af; margin-bottom: 8px; letter-spacing: 0.3px;">
                            Trader-Focused Analysis:
                        </div>
                        <div style="font-size: 11px; color: #334155; line-height: 1.6; margin-bottom: 8px;">
                            Each RNS includes sentiment classification, key data extraction, and trading context. 
                            Color-coded badges indicate bullish (green), bearish (red), or neutral (blue) signals.
                        </div>
                        <div style="
                            font-size: 10px; 
                            color: #dc2626; 
                            font-weight: 600; 
                            padding: 6px 10px;
                            background: rgba(239, 68, 68, 0.08);
                            border-left: 2px solid #ef4444;
                            border-radius: 4px;
                            margin-top: 8px;
                        ">
                            ‚ö†Ô∏è This is analysis of regulatory news for informational purposes. Not investment advice.
                        </div>
                    </div>
                </div>
            </div>
            
            <div style="margin-top: 15px;">
                
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">1</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #1
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üèõÔ∏è</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Holding(s) in Company</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">HOLDINGS</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Major holder disclosure - routine regulatory filing.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">4th Feb 2026</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">3:27 pm</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Rathbones Group</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
4 Feb 2026 15:27
RNS Number : 7532R
Fusion Antibodies PLC
04 February 2026
4 February 2026
Fusion Antibodies plc
("Fusion"
or the
"Company")
Holding(s) in Company
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, was informed today that Rathbones Investment Management Ltd (ultimately controlled by Rathbones Group Plc) now holds 9,679,837 ordinary shares of 4 pence each in the Company, representing approximately 7.74 per cent. of the Company's issued share capital. These shares are registered in the name of Rathbones Nominees Limited.
Enquiries:
Fusion Antibodies plc
www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Chief Financial Officer
Via Walbrook PR
Fusion Antibodies interactive investor hub
https://investorhub.fusionantibodies.com/
Allenby Capital Limited
Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)
Tel: +44 (0) 207 186 9952
Walbrook PR
Tel: +44 (0)20 7933 8780 or¬†fusion@walbrookpr.com
Anna Dunphy
Mob: +44 (0)7876 741 001
About Fusion Antibodies plc
Fusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers a integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.
The range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM¬†platform and¬†cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,¬†the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in
combining the latest technological advances with cutting edge science.
In this work our world-class discovery (
OptiMAL¬Æ
and OptiPhageTM), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM)
to
ensure the best molecule goes to the clinic.
Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our
Integrated Therapeutic Antibody Services ("ITA") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.
Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023.
While therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
HOLUPUAPPUPQGAC
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">2</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #2
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üèõÔ∏è</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Holding(s) in Company</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">HOLDINGS</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Major holder disclosure - routine regulatory filing.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">2nd Feb 2026</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">11:33 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">See Section</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">6.66%, 6.66%, 5.65%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
2 Feb 2026 11:33
RNS Number : 3413R
Fusion Antibodies PLC
02 February 2026
TR-1: S
tandard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS
(to be sent to the relevant issuer
and
to the FCA in Microsoft Word format if possible)
i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached
ii
:
Fusion Antibodies plc
1b. Please indicate if the issuer is a non-UK issuer
(please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification
(please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
X
Other (please specify)iii:
3. Details of person subject to the notification obligation
iv
Name
Unicorn Asset Management Limited
City and country of registered office (if applicable)
London, United Kingdom
4. Full name of shareholder(s)
(if different from 3.)
v
Name
Unicorn AIM VCT plc
City and country of registered office (if applicable)
Teignmouth, Devon, United Kingdom
5. Date on which the threshold was crossed or reached
vi
:
30 January 2026
6.
Date on which issuer notified (DD/MM/YYYY):
02 February 2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A)
% of
voting rights through
financial instruments(total of 8.B 1 + 8.B 2)
Total of both in % (8.A + 8.B)
Total number of voting rights held in issuer (8.A + 8.B)
vii
Resulting situation on the date on which threshold was crossed or reached
6.66%
6.66%
8,320,366
Position of previous notification (if
applicable)
5.65%
5.65%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached
viii
A: Voting rights attached to shares
Class/type ofshares
ISIN code (if possible)
Number of voting rights
ix
% of voting rights
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Direct
(Art 9 of Directive 2004/109/EC) (DTR5.1)
Indirect
(Art 10 of Directive 2004/109/EC) (DTR5.2.1)
Ordinary shares
GB00BDQZGK16
8,320,366
6.66%
SUBTOTAL 8. A
8,320,366
6.66%
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))
Type of financial instrument
Expirationdate
x
Exercise/Conversion Period
xi
Number of voting rights that may be acquired if the instrument is
exercised/converted.
% of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of financial instrument
Expirationdate
x
Exercise/Conversion Period
xi
Physical or cash
settlement
xii
Number of voting rights
% of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation
(please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer
xiii
X
Full
chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv
(please add additional rows as necessary)
Name
xv
% of voting rights if it equals or is higher than the notifiable threshold
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold
Total of both if it equals or is higher than the notifiable threshold
10.
In case of proxy voting, please identify:
Name of the proxy holder
See Section 4
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information
xvi
Figures are based on total voting rights of 125,021,878
Place of completion
Unicorn Asset Management Limited, Preachers Court, Charterhouse, Chartehouse Square, London, EC1M 6AU
Date of completion
02 February 2026
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
HOLUPUGWPUPQGGP
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">3</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #3
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Total Voting Rights</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">30th Jan 2026</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">5:00 pm</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Antibody Services</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
Today 17:00
RNS Number : 1535R
Fusion Antibodies PLC
30 January 2026
30 January 2026
Fusion Antibodies plc
("Fusion"
or the
"Company")
Total Voting Rights
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces¬†that the issued share capital of the Company at the date of this announcement comprises
125,021,878
ordinary shares of¬†4 pence each with one voting right per share ("Ordinary Shares"). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company is
125,021,878
.
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Fusion Antibodies plc
www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Chief Financial Officer
Via Walbrook PR
Fusion Antibodies interactive investor hub
https://investorhub.fusionantibodies.com/
Allenby Capital Limited
Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)
Tel: +44 (0) 207 186 9952
Walbrook PR
Tel: +44 (0)20 7933 8780 or¬†fusion@walbrookpr.com
Anna Dunphy
Mob: +44 (0)7876 741 001
About Fusion Antibodies plc
Fusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.
The range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM¬†platform and¬†cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,¬†the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in
combining the latest technological advances with cutting edge science.
In this work our world-class discovery (
OptiMAL¬Æ
and OptiPhageTM), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM)
to
ensure the best molecule goes to the clinic.
Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our
Integrated Therapeutic Antibody Services ("ITA") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.
Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023.
While therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
TVRBSGDBGSXDGLG
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">4</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #4
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üë•</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Issue of Director Shares</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">APPOINTMENT</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">27th Jan 2026</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:05 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Director Shares</td>
                    </tr>
                    
                        <tr style="border-bottom: 1px solid #e2e8f0;">
                            <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">ACTION:</td>
                            <td style="padding: 8px; font-weight: 600; font-size: 12px; color: #3b82f6;">DISPOSAL</td>
                        </tr>
                        
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">20%, 45%, 40%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
27 Jan 2026 07:05
RNS Number : 4327Q
Fusion Antibodies PLC
27 January 2026
27 January 2026
Fusion Antibodies plc
("Fusion"
or the
"Company")
Issue of Director Shares
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,
announces, further to the notification of the conditional placing and subscription to raise approximately ¬£1.4 million (before expenses) (the "
Fundraise
") released earlier today (the "
Fundraise Announcement
"), the Company has issued 308,720 new ordinary shares of 4p each in the share capital of the Company ("
Ordinary Shares
") to certain
executive Directors at a deemed subscription price equal to the Fundraise issue price of 13 pence per new Ordinary Share (the "
Issue Price
") in satisfaction of a portion of their bonuses for the year ended 31 March 2025 (the "
Director
Shares
").
As disclosed in the Company's annual report and accounts for the year ended 31 March 2025 (as announced on 4 September 2025), the remuneration committee recommended, and the board of directors of Fusion (the "
Board
" or the "
Directors
") accepted, a bonus award for Adrian Kinkaid (CEO) and Richard Buick (CSO) each of 20% of their gross salary, against their maximum contractual bonus of 45% and 40% respectively. In recognition that the Company is still controlling costs tightly and cognisant of the cash position, it was agreed that the bonus award be split into two components: 40% cash and the remainder to be satisfied via the issue of new Ordinary Shares once the Company was in an open period.
As separately indicated in Fundraise Announcement, the Board has now resolved to issue and allot, in aggregate,
308,720
new Ordinary Shares to Adrian Kinkaid (CEO) and Richard Buick (CSO) at a deemed issue price equal to the Issue Price and pursuant to the authorities previously granted at the
Company's annual general meeting held on 16 October 2025,
as follows:
Director
Amount of bonus award to be received in Director Shares
No. of Director Shares issued
Total holding of Ordinary Shares post issue
Percentage of enlarged issued share capital1
Adrian Kinkaid
¬£23,846.94
183,438
1,033,438
0.83%
Richard Buick
¬£16,286.66
125,282
1,125,282
0.90%
1
Based on the enlarged issued share capital of the Company following the issue of the Director Shares, the Placing Shares and the Subscription Shares, as defined in the Fundraise Announcement.
Admission to trading on AIM
Application has been made to the London Stock Exchange plc for the New Ordinary Shares to be admitted to trading on AIM ("
Admission
"). It is currently anticipated that Admission will become effective and that dealings in the New Ordinary Shares will commence on AIM at 8.00 a.m. on or around
30
January 2026.
Total voting rights
On Admission, the Company will have 125,021,878 Ordinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 125,021,878 and this figure may be used by shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Defined terms in this announcement shall have the same meaning as defined in the Fundraise Announcement, unless otherwise defined herein.
Enquiries:
Fusion Antibodies plc
www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Chief Financial Officer
Via Walbrook PR
Fusion Antibodies interactive investor hub
https://investorhub.fusionantibodies.com/
Allenby Capital Limited
Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)
Tel: +44 (0) 207 186 9952
Walbrook PR
Tel: +44 (0)20 7933 8780 or¬†fusion@walbrookpr.com
Anna Dunphy
Mob: +44 (0)7876 741 001
Director/PDMR UK MAR disclosures
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
1.
Adrian Kinkaid
2.
Richard Buick
2
Reason for the notification
a)
Position/status
1. Chief Executive Officer
2.
Chief Scientific Officer
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Fusion Antibodies plc
b)
LEI
213800KBAYRC9VOQ9V39
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 4p each in Fusion Antibodies plc
Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16
b)
Nature of the transaction
Issue of Director Shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1.
1
3 pence
183,438
2.
1
3 pence
125,282
d)
Aggregated information:
- Aggregated volume
- Price
N/A
e)
Date of the transaction
27 January 2026,
to be completed on 30 January 2026
f)
Place of the transaction
Outside a trading venue
About Fusion Antibodies plc
Fusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers a integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.
The range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM¬†platform and¬†cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,¬†the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in
combining the latest technological advances with cutting edge science.
In this work our world-class discovery (
OptiMAL¬Æ
and OptiPhageTM), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM)
to
ensure the best molecule goes to the clinic.
Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our
Integrated Therapeutic Antibody Services ("ITA") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.
Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023.
While therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
DSHAKABNOBKDBDB
                </div>
            </details>
            
            </div>
            
            <div style="
                margin-bottom: 20px;
                padding: 18px;
                background: white;
                border-radius: 14px;
                border: 1px solid #e2e8f0;
                box-shadow: 0 1px 3px rgba(0,0,0,0.05);
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 14px;">
                    <span style="
                        display: inline-flex;
                        align-items: center;
                        justify-content: center;
                        width: 30px;
                        height: 30px;
                        background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                        color: white;
                        border-radius: 50%;
                        font-weight: 800;
                        font-size: 15px;
                        box-shadow: 0 2px 8px #3b82f640;
                    ">5</span>
                    <div style="font-size: 11px; color: #94a3b8; font-weight: 600; letter-spacing: 0.5px;">
                        RNS ANNOUNCEMENT #5
                    </div>
                </div>
                
                
            <div style="
                background: linear-gradient(135deg, #3b82f6 0%, #3b82f6dd 100%);
                color: white;
                padding: 14px;
                border-radius: 10px;
                margin-bottom: 16px;
            ">
                <div style="display: flex; align-items: center; gap: 10px; margin-bottom: 8px;">
                    <span style="font-size: 20px;">üì∞</span>
                    <div style="flex: 1;">
                        <div style="font-weight: 700; font-size: 16px;">Placing and Subscription to raise approx ¬£1.4m</div>
                        <span style="
                            display: inline-block;
                            background: rgba(255,255,255,0.25);
                            padding: 2px 10px;
                            border-radius: 12px;
                            font-size: 11px;
                            margin-top: 4px;
                            font-weight: 600;
                        ">UPDATE</span>
                    </div>
                </div>
                <div style="font-size: 13px; opacity: 0.95; line-height: 1.4;">
                    Informational update - monitor for context with other announcements.
                </div>
            </div>
            
                
            <div style="
                display: grid;
                grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
                gap: 10px;
                margin: 16px 0;
            ">
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">DATE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">27th Jan 2026</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">TIME</div>
                    <div style="font-weight: 700; font-size: 13px; color: #0f172a;">7:00 am</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SOURCE</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">RNS</div>
                </div>
                <div style="padding: 10px; background: #f8fafc; border-radius: 8px;">
                    <div style="font-size: 10px; color: #64748b; margin-bottom: 4px; font-weight: 600;">SENTIMENT</div>
                    <div style="font-weight: 700; font-size: 13px; color: #3b82f6;">NEUTRAL</div>
                </div>
            </div>
            
                
                
                    <div style="margin: 16px 0;">
                        <h4 style="font-size: 14px; color: #1e293b; margin-bottom: 10px; font-weight: 700;">üìä Key Data Points:</h4>
                        <table style="width: 100%; border-collapse: collapse; font-size: 13px; background: white; border-radius: 8px; overflow: hidden;">
                            
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">PERSON/ENTITY:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">Colin Walsh</td>
                    </tr>
                    
                    <tr style="border-bottom: 1px solid #e2e8f0;">
                        <td style="padding: 8px; color: #64748b; font-weight: 600; font-size: 12px;">KEY METRICS:</td>
                        <td style="padding: 8px; font-weight: 600; font-size: 12px;">2.82%, 20%, 45%</td>
                    </tr>
                    
                        </table>
                    </div>
                    
                
            <details style="margin-top: 16px;">
                <summary style="
                    padding: 10px;
                    background: #f8fafc;
                    border-radius: 8px;
                    font-weight: 600;
                    font-size: 12px;
                    list-style: none;
                    cursor: pointer;
                    color: #64748b;
                    border: 1px solid #e2e8f0;
                ">
                    üìÑ View Full RNS Text
                </summary>
                <div style="
                    margin-top: 8px;
                    padding: 14px;
                    background: #f1f5f9;
                    border-radius: 8px;
                    font-family: 'Courier New', monospace;
                    font-size: 11px;
                    line-height: 1.5;
                    color: #475569;
                    max-height: 300px;
                    overflow-y: auto;
                    white-space: pre-wrap;
                    word-wrap: break-word;
                ">
27 Jan 2026 07:00
RNS Number : 4325Q
Fusion Antibodies PLC
27 January 2026
THIS ANNOUNCEMENT IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("EUWA")) ("UK MAR"). IN ADDITION, MARKET SOUNDINGS (AS DEFINED IN UK MAR) WERE TAKEN IN RESPECT OF CERTAIN OF THE MATTERS CONTAINED WITHIN THIS ANNOUNCEMENT, WITH THE RESULT THAT CERTAIN PERSONS BECAME AWARE OF INSIDE INFORMATION (AS DEFINED UNDER UK MAR). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THOSE PERSONS THAT RECEIVED INSIDE INFORMATION IN A MARKET SOUNDING ARE NO LONGER IN POSSESSION OF SUCH INSIDE INFORMATION, WHICH IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
27 January 2026
Fusion Antibodies plc
("Fusion"
or the
"Company")
Placing and Subscription to raise approximately ¬£1.4 million
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications,
announces
that it has conditionally raised approximately ¬£1.4
million (before expenses)
through the issue of
11,056,905
new ordinary shares of 4 pence each in the
Company ("
Ordinary Shares
") at a
price of 13 pence per new Ordinary Share
(the "
Issue Price
"), as follows:
¬∑
approximately ¬£1.4 million (before expenses) has been raised by way of a placing of a total of 10,904,121 new Ordinary Shares (the "
Placing Shares
") at the Issue Price with new investors and existing shareholders (the "
Placing
"); and
¬∑
Colin Walsh, Non-Executive Director, has directly subscribed with the Company for
152,784
new Ordinary Shares (the "
Subscription Shares
") at the Issue Price (the "
Subscription
", and together with the Placing, the "
Fundraise
"), raising ¬£19,861.92 (before expenses).
Allenby Capital Limited ("
Allenby Capital
") and Shard Capital Partners LLP ("
Shard
") are acting as the Company's joint brokers in connection with the Placing.
Key highlights
¬∑
Placing and Subscription to raise approximately ¬£
1.4 million
(before expenses) through the issue of
11,056,905 new Ordinary
Shares at the Issue Price.
¬∑
The Issue Price is equal to the closing bid price of an Ordinary Share on
26
January 2026.
¬∑
The Fundraise is being conducted utilising all of the existing share authorities available to the Board to issue shares for cash on a non-pre-emptive basis, as approved at the Company's annual general meeting held on 16 October 2025 (the "
2025 AGM
").
¬∑
Shortly following the publication of this announcement, the Company intends to issue 308,720 new Ordinary Shares (the "
Director Shares
") to certain executive directors at a deemed subscription price equal to the Issue Price in satisfaction of a portion of their bonuses for the year ended 31 March 2025, further details of which are outlined below.
¬∑
The Placing is not being underwritten by Allenby Capital or Shard.
Adrian Kinkaid, Chief Executive Officer of Fusion Antibodies plc, commented:
"
The successful validation and formal launch of our OptiMAL¬Æ platform marks a significant milestone for Fusion Antibodies. Strong interest from potential partners reinforce our confidence in the platform's ability to generate solid revenues and transform our business over time.
"This fundraise, which has been supported by a number of our longstanding shareholders, will allow us to accelerate commercialisation, invest in strategic partnerships and targeted global marketing; and further strengthen our proprietary technologies. This will place the Company in a strong position for sustainable growth and help to generate long term value for our shareholders."
Further details of the Fundraise are set out below.
Background to and reasons for the
Fundraise
Through the successful collaboration with the National Cancer Institute ("
NCI
") in the United Sates, the directors of the Company (the "
Directors
" or together, the "
Board
") believe that the Company has now validated the OptiMAL¬Æ platform with the platform performing in line with and in certain instances exceeding target performance parameters laid out by the Company.
The formal launch of the OptiMAL¬Æ platform took place on 15 December 2025 at the Antibody Engineering and Therapeutics conference in San Diego, an established conference which attracts a wide range of technical experts in the antibody discovery field. Fusion's attendance at the conference generated significant interest in both the OptiMAL¬Æ platform and the Company as well as provided further encouragement that the OptiMAL¬Æ platform has every prospect of potential material revenue generation and the potential to favourably transform Fusion's business over time.
The Directors believe that the initial soundings and market research, including discussions with a number of potential clients, have been very positive. Many of the organizations approached in the pre-launch phase have expressed an interest in the OptiMAL¬Æ platform including disclosure of target details under non-disclosure agreements, resulting in multiple opportunities being registered in the Company's sales opportunities pipeline, which has a combined potential value in excess of ¬£1 million. While these opportunities remain at an early stage and will take some time to convert (if at all), the level of interest in the OptiMAL¬Æ platform provides encouraging signs of the commercial potential of this platform.
Against the backdrop of the formal launch of the OptiMAL¬Æ platform and the reasons outlined above, the Board believes that it is well positioned for significant growth but remains cautiously mindful of the potential market volatility and the inherent science-based risks in the work being undertaken by its clients, which can potentially impact the visibility of revenue streams.
The Board is aware of the significant advantages that the Company's proprietary platforms including OptiMAL¬Æ, OptiPhageTM and AI/ML-abTM can provide to clients in their pursuit of new antibody therapeutics and so are supportive of accelerating the commercialisation of these platforms starting with OptiMAL¬Æ.
Reasons for the
Fundraise
As previously announced, it had been a key focus of the Board for the Company to achieve cash flow breakeven without needing to raise additional funds. While the Company was on track to achieve this, the extremely tight control of costs that would have been required would impact on the speed of the roll out of a commercially robust OptiMAL¬Æ platform by the Company and the dedicated marketing activities required post formal launch. The Board considers that it is in the best interests of the Company and its shareholders to conduct the Fundraise in order to provide the capital for the commercialisation of the OptiMAL¬Æ platform, associated equipment and global marketing activities, to improve the overall cash position of the business and provide it with increased working capital to generate supporting data for its key proprietary platforms, namely OptiMAL¬Æ, OptiPhageTM and Mammalian Display.
Use of proceeds
The net proceeds receivable by the Company pursuant to the Fundraise, being approximately ¬£1.3 million, will be used for the purchase of certain laboratory equipment to enhance the efficiency of the OptiMAL¬Æ platform, to invest in the Company's commercial activities and for general working capital purposes. The commercial plans will focus on increasing the Company's presence in key geographic markets, such as North America, and promoting OptiMAL¬Æ through various marketing activities, including but not limited to, attendance at key industry conferences and follow on business development trips.
Details of the Placing and the Subscription
The Placing will result in the issue of a total of 10,904,121 Placing Shares and the Subscription will result in the issue of 152,784 Subscription Shares, in each case at the Issue Price. Together, the Placing and Subscription has raised ¬£1,437,397.65 before expenses for the Company. The Placing Shares and the Subscription Shares will be issued on a non-pre-emptive basis pursuant to the authorities granted to the Board at the 2025 AGM.
The Placing Shares and the Subscription Shares, when issued and fully paid, will rank
pari passu
in all respects with the existing Ordinary Shares in issue and therefore will rank equally for all dividends or other distributions declared, made or paid after the issue of the Placing Shares and the Subscription Shares.
Allenby Capital and Shard have entered into a Placing Agreement with the Company pursuant to which Allenby Capital and Shard have, on the terms and subject to the conditions set out therein, undertaken to use their respective reasonable endeavours to procure subscribers for the Placing Shares at the Issue Price. The Placing Agreement contains certain warranties and indemnities from the Company in favour of Allenby Capital and Shard. The Placing is not being underwritten by Allenby Capital, Shard or any other person.
Director participation in the Subscription
Colin Walsh, a Non-Executive Director of the Company, has subscribed for 152,784 Subscription Shares at the Issue Price pursuant to the Subscription. Following Admission (as defined below), Mr Walsh will have a total direct and indirect beneficial interest in 3,531,785 Ordinary Shares, equivalent to approximately 2.82% of Fusion's total issued ordinary share capital (as enlarged by the issue of the Placing Shares, the Subscription Shares and the Director Shares). 715,284 of these Ordinary Shares are held directly, 211,618 are held by Crescent Capital III GP Limited ("
Crescent III Ltd
"), which is controlled by Mr Walsh, 1,204,883 are held by Walsh Strategic Management Limited ("
WSML
"), another company controlled by Mr Walsh and 1,400,000 are held by HamNiv (GP) Limited, a subsidiary of Crescent Capital NI Limited. Mr Walsh is the founder and Chief Executive Officer of Crescent Capital NI Limited.
The tables below, which have been provided in accordance with the requirements of the UK Market Abuse Regulation, provide further details of the transactions.
Proposed issue of Director Shares
As disclosed in the Company's annual report and accounts for the year ended 31 March 2025, the remuneration committee recommended, and the Board accepted, a bonus award for Adrian Kinkaid (CEO) and Richard Buick (CSO) each of 20% of their gross salary, against their maximum contractual bonus of 45% and 40% respectively. In recognition that the Company is still controlling costs tightly and cognisant of the cash position, it was agreed that the bonus award be split into two components: 40% cash and the remainder to be satisfied via the issue of new Ordinary Shares once the Company was in an open period.
Therefore, immediately following the publication of this announcement, 308,720 new Ordinary Shares will be issued and allotted to Adrian Kinkaid (CEO) and Richard Buick (CSO) at a deemed subscription price equal to the Issue Price and pursuant to the authorities previously granted at the 2025 AGM, as follows:
Director
Amount of bonus award to be received in Director Shares
No. of Director Shares to be issued
Adrian Kinkaid
¬£23,846.94
183,438
Richard Buick
¬£16,286.66
125,282
A further announcement will be provided following the issue and allotment of the Director Shares.
Admission to trading on AIM
Application will be made to the London Stock Exchange plc for the Placing Shares, the Subscription Shares and, once issued, the Director Shares (together, the "
New Ordinary Shares
") to be admitted to trading on AIM ("
Admission
"). It is currently anticipated that Admission will become effective and that dealings in the New Ordinary Shares will commence on AIM at 8.00 a.m. on or around
30 January
2026.
Total voting rights
On Admission, the Company will have 125,021,878 Ordinary Shares in issue, each with one voting right. There are no shares held in treasury. Therefore, the Company's total number of Ordinary Shares in issue and voting rights will be 125,021,878 and this figure may be used by shareholders from Admission as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Enquiries:
Fusion Antibodies plc
www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer
Stephen Smyth, Chief Financial Officer
Via Walbrook PR
Fusion Antibodies interactive investor hub
https://investorhub.fusionantibodies.com/
Allenby Capital Limited
Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)
Tel: +44 (0) 207 186 9952
Walbrook PR
Tel: +44 (0)20 7933 8780 or
fusion@walbrookpr.com
Anna Dunphy
Mob: +44 (0)7876 741 001
This announcement is made in accordance with the Company's obligations under Article 17 of UK MAR and the person responsible for arranging for the release of this announcement on behalf of Fusion is Adrian Kinkaid, Chief Executive Officer.
Director/PDMR UK MAR disclosures
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Colin Walsh
2
Reason for the notification
a)
Position/status
Non-Executive Director
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Fusion Antibodies plc
b)
LEI
213800KBAYRC9VOQ9V39
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 4p each in Fusion Antibodies plc
Identification code (ISIN) for Fusion Antibodies plc ordinary shares: GB00BDQZGK16
b)
Nature of the transaction
Purchase of new Ordinary Shares
c)
Price(s) and volume(s)
Price(s)
Volume(s)
1
3p
1
52,784
d)
Aggregated information:
- Aggregated volume
- Price
N/A
e)
Date of the transaction
2
6
January 2026 to be completed on 30 January 2026
f)
Place of the transaction
Outside a trading venue
IMPORTANT NOTICES
Notice to Distributors
Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended and as this is applied in the United Kingdom ("
MiFID II
"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II and Regulation (EU) No 600/2014 of the European Parliament, as they form part of UK law by virtue of the European Union (Withdrawal) Act 2018, as amended; and (c) local implementing measures (together, the "
MiFID II Product Governance Requirements
"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "
manufacturer
" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the Ordinary Shares have been subject to a product approval process, which has determined that such securities are: (i) compatible with an end target market of retail investors who do not need a guaranteed income or capital protection and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "
Target Market Assessment
"). The Ordinary Shares are not appropriate for a target market of investors whose objectives include no capital loss. Notwithstanding the Target Market Assessment, distributors should note that: the price of the Ordinary Shares may decline and investors could lose all or part of their investment; the Ordinary Shares offer no guaranteed income and no capital protection; and an investment in the Ordinary Shares is compatible only with investors who do not need a guaranteed income or capital projection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Fundraise. Furthermore, it is noted that, notwithstanding the Target Market Assessment, Allenby Capital and Shard will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Ordinary Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the shares and determining appropriate distribution channels.
Forward Looking Statements
This announcement includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "plans", "anticipates", "targets", "aims", "continues", "expects", "intends", "hopes", "may", "will", "would", "could" or "should" or, in each case, their negative or other variations or comparable terminology. These forward-looking statements include matters that are not facts. They appear in a number of places throughout this announcement and include statements regarding the Directors' beliefs or current expectations. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this announcement.
Notice to overseas persons
This announcement does not constitute, or form part of, a prospectus relating to the Company, nor does it constitute or contain any invitation or offer to any person, or any public offer, to subscribe for, purchase or otherwise acquire any shares in the Company or advise persons to do so in any jurisdiction, nor shall it, or any part of it form the basis of or be relied on in connection with any contract or as an inducement to enter into any contract or commitment with the Company.
This announcement is not for release, publication or distribution, in whole or in part, directly or indirectly, in or into Australia, Canada, Japan, New Zealand or the Republic of South Africa or any jurisdiction into which the publication or distribution would be unlawful. This announcement is for information purposes only and does not constitute an offer to sell or issue or the solicitation of an offer to buy or acquire shares in the capital of the Company in Australia, Canada, Japan, New Zealand, the Republic of South Africa or any jurisdiction in which such offer or solicitation would be unlawful or require preparation of any prospectus or other offer documentation or would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. Persons into whose possession this announcement comes are required by the Company to inform themselves about, and to observe, such restrictions.
This announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.
General
Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) or any previous announcement made by the Company is incorporated into, or forms part of, this announcement.
Allenby Capital, which is authorised and regulated by the FCA in the United Kingdom, is acting as Nominated Adviser and Joint Broker to the Company in connection with the Placing. Allenby Capital will not be responsible to any person other than the Company for providing the protections afforded to clients of Allenby Capital or for providing advice to any other person in connection with the Fundraise. Allenby Capital has not authorised the contents of, or any part of, this announcement, and no liability whatsoever is accepted by Allenby Capital for the accuracy of any information or opinions contained in this announcement or for the omission of any material information, save that nothing shall limit the liability of Allenby Capital for its own fraud.
Shard, which is authorised and regulated by the FCA in the United Kingdom, is acting as¬†Joint Broker to the Company¬†in connection with the Placing. Shard will not be responsible to any person other than the Company for providing the protections afforded to clients of Shard or for providing advice to any other person in connection with the Fundraise. Shard has not authorised the contents of, or any part of, this announcement, and no liability whatsoever is accepted by Shard for the accuracy of any information or opinions contained in this announcement or for the omission of any material information, save that nothing shall limit the liability of Shard for its own fraud.
About Fusion Antibodies plc
Fusion Antibodies plc is a Contract Research Organisation (CRO) located in Northern Ireland that offers a integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development.
The range of services offered includes antibody discovery/generation, development, characterisation, optimisation, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanisation using Fusion's proprietary CDRxTM¬†platform and¬†cell line development, producing antibody generating stable cell lines optimised for use downstream by the customer to produce material for clinical trials. Since 2012,¬†the Company has successfully sequenced and expressed many thousands of antibodies and successfully completed over 290 humanisation projects for its international customer base, which has included eight of the top 10 global pharmaceutical companies by revenue.
At every stage, our client's vision is central to how we work in
combining the latest technological advances with cutting edge science.
In this work our world-class discovery (
OptiMAL¬Æ
and OptiPhageTM), humanization and antibody optimization platforms harness the power of natural somatic hypermutation (SHM)
to
ensure the best molecule goes to the clinic.
Fusion Antibodies' growth strategy is based on enabling Pharma and Biotech companies get to the clinic more effectively, using molecules with optimized therapeutic profile and enhanced potential for successful development and approval and, ultimately, on speeding up the drug discovery and development process. Our
Integrated Therapeutic Antibody Services ("ITA") offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.
Fusion's use of SHM to create a fully human antibody library to capture the human antibody repertoire addresses a continuing market need in antibody discovery.
Fusion Antibodies' emphasis on antibody therapeutics is based on the size and growth rate in the sector, with the market valued at $253 billion in 2024 and forecast to reach nearly $500 billion by 2029. From 2020 to 2024 there have been 63 antibody therapeutics granted approval in either the USA or the EU, of which 30 were for cancer and there were nine antibodies each with sales of more than $5 billion in 2023.
While therapeutic antibodies are our primary focus, all the services are directly applicable to the Diagnostic sector and also the new, more embryonic veterinary markets and diversification into these markets gives the Company further growth opportunities.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com
or visit
www.rns.com
.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy
.
END
IOESEFFWMEMSEDF
                </div>
            </details>
            
            </div>
            
            </div>
        </div>
        
        <style>
            @keyframes slideDown {
                from {
                    opacity: 0;
                    transform: translateY(-10px);
                }
                to {
                    opacity: 1;
                    transform: translateY(0);
                }
            }
            details[open] > summary {
                background: linear-gradient(135deg, #eff6ff 0%, #f0f9ff 100%) !important;
                border-left-color: #0369a1 !important;
            }
            summary::-webkit-details-marker {
                display: none;
            }
            
            /* ========== MOBILE RESPONSIVE ========== */
            @media (max-width: 768px) {
                body {
                    padding: 10px;
                    font-size: 14px;
                }
                
                .container {
                    margin: 0 auto;
                }
                
                .header-card {
                    padding: 14px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .company-name {
                    font-size: 22px;
                    margin-bottom: 8px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 13px;
                    padding: 6px 12px;
                }
                
                .company-meta {
                    gap: 8px;
                    flex-direction: row;
                    flex-wrap: wrap;
                }
                
                .meta-item {
                    padding: 6px 12px;
                    font-size: 12px;
                    gap: 6px;
                }
                
                .meta-icon {
                    font-size: 14px;
                }
                
                .score-hero {
                    padding: 20px;
                    margin-bottom: 12px;
                    border-radius: 12px;
                }
                
                .action-display {
                    font-size: 18px !important;
                    margin-bottom: 12px;
                }
                
                .scores-row {
                    gap: 16px;
                    margin: 20px 0;
                    justify-content: center;
                    flex-wrap: wrap;
                    display: flex;
                }
                
                .score-circle {
                    width: 110px;
                    height: 110px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 32px;
                }
                
                .score-label {
                    font-size: 10px;
                    margin-top: 4px;
                }
                
                .timing-badge-large {
                    padding: 10px 20px;
                    font-size: 14px;
                    margin: 12px 0;
                }
                
                .thesis-line {
                    font-size: 14px;
                    padding: 12px;
                    margin-top: 12px;
                }
                
                .factors-list {
                    grid-template-columns: 1fr;
                    gap: 10px;
                    margin-top: 12px;
                }
                
                .factor-item {
                    padding: 12px;
                    font-size: 12px;
                    gap: 8px;
                }
                
                .factor-icon {
                    font-size: 16px;
                }
                
                .cards-grid {
                    grid-template-columns: 1fr;
                    gap: 12px;
                    margin-bottom: 12px;
                }
                
                .card {
                    padding: 16px;
                    border-radius: 12px;
                }
                
                .card-title {
                    font-size: 14px;
                    margin-bottom: 12px;
                    gap: 8px;
                }
                
                .card-icon {
                    font-size: 18px;
                }
                
                .stat-row {
                    padding: 8px 0;
                    flex-wrap: wrap;
                    gap: 10px;
                }
                
                .stat-label {
                    font-size: 12px;
                }
                
                .stat-value {
                    font-size: 14px;
                }
                
                .rally-badge {
                    padding: 4px 10px;
                    font-size: 10px;
                }
                
                .risk-indicator {
                    gap: 10px;
                    padding: 12px;
                    flex-wrap: wrap;
                }
                
                .risk-icon {
                    font-size: 20px;
                }
                
                .reason-item {
                    padding: 12px;
                    margin-bottom: 10px;
                }
                
                .tag {
                    padding: 3px 8px;
                    font-size: 10px;
                }
                
                .footer {
                    padding: 12px;
                    font-size: 11px;
                    margin-top: 12px;
                    border-radius: 12px;
                }
                
                .alert-box {
                    padding: 12px;
                    margin: 10px 0;
                }
            }
            
            @media (max-width: 480px) {
                body {
                    padding: 8px 6px;
                }
                
                .header-card {
                    padding: 10px;
                    margin-bottom: 10px;
                    border-radius: 8px;
                }
                
                .company-name {
                    font-size: 18px;
                    margin-bottom: 6px;
                    line-height: 1.2;
                }
                
                .ticker-badge {
                    font-size: 11px;
                    padding: 3px 8px;
                }
                
                .company-meta {
                    gap: 4px;
                    flex-direction: column;
                }
                
                .meta-item {
                    padding: 4px 6px;
                    font-size: 11px;
                    background: rgba(247, 250, 252, 0.7);
                }
                
                .score-hero {
                    padding: 12px;
                    margin-bottom: 10px;
                    border-radius: 12px;
                }
                
                .score-circle {
                    width: 70px;
                    height: 70px;
                    flex-shrink: 0;
                }
                
                .score-number {
                    font-size: 22px;
                    font-weight: 800;
                }
                
                .score-label {
                    font-size: 7px;
                    margin-top: 2px;
                }
                
                .scores-row {
                    flex-direction: column;
                    gap: 10px;
                    margin: 12px 0;
                    align-items: center;
                }
                
                .timing-badge-large {
                    padding: 6px 12px;
                    font-size: 11px;
                    margin: 10px 0;
                }
                
                .thesis-line {
                    font-size: 11px;
                    padding: 8px;
                    line-height: 1.3;
                }
                
                .card {
                    padding: 10px;
                    margin-bottom: 8px;
                    border-radius: 8px;
                }
                
                .card-title {
                    font-size: 12px;
                    margin-bottom: 8px;
                    font-weight: 700;
                }
            }
        </style>
        

        <!-- Footer -->
        <div class="footer">
            Report generated: 2026-02-11 ‚Ä¢ CrashDash APEX Engine (Advanced Pattern EXploration)<br>
            <strong>‚ñ≥ Not financial advice. Do your own research.</strong>
            <div style="margin-top: 12px; padding-top: 12px; border-top: 1px solid #e5e7eb; font-size: 11px; color: #999; line-height: 1.5;">
                <strong>APEX</strong> is a CrashDash AI-powered quantitative intelligence platform that analyzes multi-source market signals using advanced pattern recognition. Designed for professional traders and institutional users, it synthesizes technical, sentiment, and fundamental data into actionable market profiles‚Äîready for seamless integration into workflows.
            </div>
        </div>

    </div>
</body>
</html>